The stock of Pfizer Inc. (NYSE:PFE) is a huge mover today! About 7.06M shares traded hands. Pfizer Inc. (NYSE:PFE) has declined 4.57% since April 26, 2016 and is downtrending. It has underperformed by 9.83% the S&P500.
The move comes after 8 months positive chart setup for the $192.09B company. It was reported on Nov, 29 by Barchart.com. We have $34.35 PT which if reached, will make NYSE:PFE worth $15.37B more.
Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on February, 7. They expect $0.50 EPS, down 5.66% or $0.03 from last year’s $0.53 per share. PFE’s profit will be $3.02B for 15.91 P/E if the $0.50 EPS becomes a reality. After $0.61 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -18.03% negative EPS growth.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
Out of 18 analysts covering Pfizer (NYSE:PFE), 7 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 39% are positive. Pfizer has been the topic of 38 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock with “Buy” rating in Thursday, April 7 report. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by Societe Generale on Wednesday, April 6. The firm has “Outperform” rating by Credit Suisse given on Monday, May 9. On Thursday, October 13 the stock rating was downgraded by Jefferies to “Hold”. Argus Research maintained Pfizer Inc. (NYSE:PFE) on Tuesday, November 3 with “Buy” rating. Barclays Capital initiated the stock with “Equal-Weight” rating in Tuesday, December 1 report. Argus Research maintained it with “Buy” rating and $41 target price in Wednesday, July 29 report. The firm has “Buy” rating by Deutsche Bank given on Wednesday, October 28. Leerink Swann maintained the shares of PFE in a report on Monday, May 2 with “Market Perform” rating. The stock has “Buy” rating given by Jefferies on Tuesday, June 14.
According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1.18 in 2016 Q2. Its up 0.15, from 1.03 in 2016Q1. The ratio increased, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Geller Family Office Serv Ltd Liability Com has invested 0.16% of its portfolio in Pfizer Inc. (NYSE:PFE). Brandywine Investment Management Limited Liability Co last reported 1.66% of its portfolio in the stock. Usa Fincl Portformulas has invested 0.24% of its portfolio in Pfizer Inc. (NYSE:PFE). Sigma Planning holds 0.44% or 96,003 shares in its portfolio. The Pennsylvania-based Clark Capital Mngmt Grp has invested 1.11% in Pfizer Inc. (NYSE:PFE). Dynamic Advsr Solutions Ltd has invested 0.09% of its portfolio in Pfizer Inc. (NYSE:PFE). Notis accumulated 16,400 shares or 0.4% of the stock. Stelac Advisory Service Limited Com has invested 0.03% of its portfolio in Pfizer Inc. (NYSE:PFE). Barr E S And owns 18,660 shares or 0.08% of their US portfolio. Assetmark accumulated 35,703 shares or 0.02% of the stock. Bessemer owns 4.99 million shares or 0.96% of their US portfolio. Moreover, Rafferty Asset Ltd Liability Corp has 0.28% invested in Pfizer Inc. (NYSE:PFE) for 119,125 shares. West Family Investments holds 84,247 shares or 0.54% of its portfolio. Ironwood Invest Management Limited Liability accumulated 0.41% or 15,656 shares. Monroe National Bank & Trust And Mi accumulated 51,098 shares or 0.62% of the stock.
Insider Transactions: Since November 4, 2016, the stock had 0 insider buys, and 2 sales for $882,530 net activity. 10,000 shares were sold by MADDALUNA ANTHONY J, worth $330,000. BOURLA ALBERT had sold 18,390 shares worth $552,530 on Friday, November 4.
More important recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016, also Fool.com published article titled: “Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.”, Fool.com published: “Is Pfizer Inc.’s 6.4% Drop in October the Beginning of a Long Downtrend?” on November 07, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) was released by: Businesswire.com and their article: “Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its …” with publication date: November 21, 2016.
PFE Company Profile
Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.